Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03431740
Other study ID # 2017-01374
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date February 15, 2018
Est. completion date April 1, 2021

Study information

Verified date April 2021
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators aim to investigate the impact of thoracic radiation therapy on diffusion capacity of the lung (primary endpoint: diffusion capacity for nitric oxide, DLNO) and on exhaled nitric oxide.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date April 1, 2021
Est. primary completion date April 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - planned but not already commenced radiation therapy (RT) of the chest, with or without pre-RT surgery. - signed informed consent of the participant Exclusion Criteria: - thoracic RT in the past - treatment with immune checkpoint inhibitors - unstable condition affecting participation in the measurements

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland University Hospital of Zurich Zürich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in diffusing capacity for nitric oxide (DLNO) Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Diffusing capacity for carbon monoxide (DLCO) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Transfer Coefficient for nitric oxide (DLNO/VA) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Transfer Coefficient for carbon monoxide (DLCO/VA) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Ratio of DLNO and DLCO The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Alveolar-capillary membrane-diffusing capacity for carbon monoxide (DMCO) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Pulmonary capillary blood volume (Vc) This variable is a calculated variable. The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Alveolar Volume (VA) This variable is a calculated variable. The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Fractional concentration of exhaled nitric oxide at a flow rate of 50mL/s (FENO50) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Concentration of nitric oxide in the gas phase of the alveolar or acinar region (CANO) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Tissue concentration of nitric oxide of the airway wall (CawNO) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Airway compartment diffusing capacity of nitric oxide from the of of the airway wall to the gas stream (DawNO) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Total flux of nitric oxide in the conducting airway compartment (JawNO) The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Forced expiratory volume in 1 second The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Forced vital capacity The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
Secondary Forced expiratory flow between 25% and 75% of forced vital capacity The course over time will be described. Before start of radiation therapy (RT), at the day of end of RT, 6 weeks and 12 months after end of RT
See also
  Status Clinical Trial Phase
Recruiting NCT03212742 - Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients Phase 1/Phase 2
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT02661152 - DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. Phase 3
Withdrawn NCT02542137 - Abscopal Effect for Metastatic Small Cell Lung Cancer Phase 2
Completed NCT01212731 - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Completed NCT01168479 - FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer Phase 3
Recruiting NCT03658343 - T2* MRI Analysis for Sarcoma N/A
Completed NCT03280719 - Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT05514327 - A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL N/A
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Recruiting NCT03370926 - FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Active, not recruiting NCT02428049 - Radiation Pneumonitis After SBRT for NSCLC
Recruiting NCT04923620 - Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
Active, not recruiting NCT05371795 - Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device N/A
Recruiting NCT03210428 - Quantitative MR Imaging in Locally Advanced Cervical Cancer